Moderate to Severe Plaque Psoriasis Clinical Trial
Official title:
A Phase Ⅰb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of TLL-018 in Subjects With Moderate to Severe Plaque Psoriasis
This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 70 subjects with moderate to severe plaque psoriasis.
Successfully screened subjects will be randomized in a ratio of 2:2:2:1 and stratified to previous biologics use for psoriasis. After a 4-week screening period (day -28-0), subjects will be randomly assigned to treatment for 12 weeks. Clinical psoriasis area and severity index (PASI), Physician's Global Assessment (PGA), dermatological Quality of Life Index (DLQI), physical exams and Laboratory tests will be performed at baseline, the end of weeks 4, 8 and 12 respectively. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05020249 -
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
|
Phase 3 | |
| Completed |
NCT01202565 -
Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
|
N/A | |
| Recruiting |
NCT05258331 -
Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis
|
Phase 1 | |
| Withdrawn |
NCT03146247 -
Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients
|
Phase 4 | |
| Recruiting |
NCT04367441 -
Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01622348 -
Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT01644396 -
An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation
|
Phase 4 | |
| Recruiting |
NCT04566666 -
To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
| Active, not recruiting |
NCT05155098 -
2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
|
||
| Completed |
NCT01555606 -
An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis
|
Phase 4 | |
| Completed |
NCT02713295 -
A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece
|
||
| Completed |
NCT04967508 -
A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis
|
Phase 3 | |
| Completed |
NCT00710580 -
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
|
Phase 3 | |
| Recruiting |
NCT06109818 -
Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT01077232 -
Documentation of Humira in Psoriasis Patients in Routine Clinical Practice
|
||
| Completed |
NCT03412747 -
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
|
Phase 3 | |
| Withdrawn |
NCT04614298 -
A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 4 | |
| Completed |
NCT02982005 -
A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea
|
Phase 3 | |
| Completed |
NCT00626002 -
Open Label Continuation Study in Moderate to Severe Psoriasis
|
Phase 3 | |
| Completed |
NCT02660580 -
MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
|
Phase 3 |